Novel Adjuvants for Peptide-Based Melanoma Vaccines

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

August 31, 2001

Primary Completion Date

January 31, 2003

Study Completion Date

June 30, 2005

Conditions
Melanoma
Interventions
BIOLOGICAL

MDX-CTLA4 Antibody; Tyrosinase/gp100/MART-1 Peptides Melanoma Vaccine

Trial Locations (1)

90089

Universtiy of Southern California/Kenneth Norris, Jr. Comprehensive Cancer Center, Los Angeles

All Listed Sponsors
lead

University of Southern California

OTHER

NCT00028431 - Novel Adjuvants for Peptide-Based Melanoma Vaccines | Biotech Hunter | Biotech Hunter